本研究旨在分析中期评估对继续进行基于 177Lu 的肽受体放射性核素治疗 (PRRT) 治疗胃肠胰神经内分泌肿瘤 (GEP-NET) 的影响，并调查其在德国大学医院的使用情况。 在 119 名 GEP-NET 患者中，接受 PRRT 后，我们使用 MRI/CT/生长抑素受体成像回顾性评估了 2 个周期后重新分期的结果和治疗影响。多学科肿瘤委员会会议根据中期 PET 结果做出治疗决策。此外，还对 37 家德国大学医院进行了一项关于其中期评估实践的在线调查，重点关注管理方面的变化。在 119 名患者中，83 人完成了 4 个 PRRT 周期； 36 人在 2:27 后停止，显示 PD，3 人达到 PR 并进行手术，5 人出现毒性，1 人死亡。完成 4 个周期的患者的中位 PFS 为 38.0 个月（95% 置信区间，32.2-43.8）。 37 家接受调查的医院中有 17 家常规使用中期评估。在对 37 家德国大学医院进行的一项调查中，62% 的医院报告为 GEP-NET 患者提供 PRRT，其中 74% 在 2 个周期的 PRRT 后进行常规中期评估，主要使用 PET/CT 成像技术。 2 个 PRRT 周期后进行中期 PET有助于识别 GEP-NET 患者的早期进展。标准化中期评估实践可以增强临床结果的可比性并优化患者管理。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

This study aimed to analyze the impact of interim evaluation on the continuation of 177Lu-based peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and to survey its usage across German university hospitals.In 119 GEP-NET patients who underwent PRRT, we retrospectively assessed the results and therapeutic impact of restaging performed after 2 cycles using MRI/CT/somatostatin receptor imaging. Therapeutic decisions based on interim PET results were made in multidisciplinary tumor board meetings. Additionally, an online survey was conducted among 37 German university hospitals regarding their interim evaluation practices, focusing on the change in management.Of 119 patients, 83 completed 4 PRRT cycles; 36 stopped after 2: 27 showed PD, 3 had PR leading to surgery, 5 experienced toxicity, and 1 died. Those completing 4 cycles showed a median PFS of 38.0 months (95% confidence interval, 32.2-43.8). Seventeen of 37 surveyed hospitals routinely used interim evaluation. In a survey among 37 German university hospitals, 62% reported offering PRRT for GEP-NET patients, with 74% of these performing a routinely interim evaluation after 2 cycles of PRRT, primarily using PET/CT imaging techniques.Interim PET after 2 PRRT cycles helps to identify early progression in GEP-NET patients. Standardizing interim evaluation practices could enhance the comparability of clinical outcomes and optimize patient management.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.